About me

Marco Peviani is Associate Professor of Pharmacology at the University of Pavia, Italy. He received his PhD in 2010 from the Open University (UK) and Mario Negri Institute (Italy), studying preclinical models of Amyotrophic Lateral Sclerosis (ALS). As a post-doc at the University of Pavia, he validated Sigma-1 receptor as a therapeutic target for ALS. In 2014, he moved to San Raffaele Institute, and then he joined the gene therapy program at Dana-Farber/Boston Children’s hospital and Harvard as an instructor, to optimize a new gene therapy approach for neuronal ceroid lipofuscinosis. Since 2019, he is head of the Cellular and Molecular Neuropharmacology Lab at the University of Pavia. His major research focus is on the development of new gene/drug-delivery tools and MRI/PET tracers for neurodegenerative disorders.